索拉非尼联合经导管肝动脉化疗栓塞治疗肝转移癌的疗效观察  

Effect analysis of sorafenib combined with TACE in treatment for liver metastatic carcinoma

作　　者：吴英超[1] 独建库[1] 马小桔[1] 

机构地区：[1]中国人民解放军第150中心医院,471031

出　　处：《山西医药杂志（上半月）》2013年第10期1103-1105,共3页Shanxi Medical Journal

摘　　要：目的探讨经导管肝动脉化疗栓塞（TACE）联合索拉非尼治疗肝转移癌的疗效和安全性。方法对2007年3月至2009年4月，78例肝转移癌患者的临床资料进行分析，其中男性46例，女性32例，年龄33～79岁，平均（58±6）岁；肿瘤直径3.6～13.5 cm ，平均（6±3）cm。其中单发转移癌17例，多发转移癌61例。患者均为全身化疗失败或无法耐受，且无其他脏器转移者。对比TACE术后口服索拉非尼的39例肝转移癌患者（联合组）和另同期行TACE的39例肝转移癌患者（对照组）的疗效。每6～8周复查1次，评价肝功能，治疗效果及CT、数字减影血管造影（DSA）和不良反应。用SPSS 13.0软件统计计算中位生存时间，平均生存时间和疾病进展时间。结果随访至2011年5月，联合组21例患者存活（54％），18例（含失访）死亡（46％）；对照组12例存活（31％），27例（含失访）死亡（69％）；至观察终点，2组均没有完全缓解病例。6、12、24个月生存率治疗组为92％（35/39），74％（29/39），49％（19/39）；对照组为82％（32/39），64％（25/39），36％（14/39）；差异有统计学意义。联合组不良反应主要表现为食欲下降、发热、乏力、皮肤反应等；对照组不良反应为恶心、呕吐、发热、疼痛等。2组不良反应经对症处理后均能够缓解。结论索拉非尼联合TACE治疗肝转移癌较单用 TACE治疗能延长患者生存期，无严重不良反应的发生。Objective To evaluate the clinical effects and safety of sorafenib combined with TACE in treat-ment for liver metastatic carcinoma .Methods From March 2007 to April 2009 ,data of 78 cases of liver metastat-ic carcinoma patients was analysed including 46 male cases and 32 female cases whose ages were range from 33 years to 79 years ,the average age of them are 58 ± 6 .Their tumour diameter is 3 .6~13 .5 cm with an average of （6 ± 3）cm .There are 17 cases solitary carcinoma and 61 cases multiple metastatic carcinoma .All the patients are systemic chemotherapy failure or unable to withstand ,and without any other organ metastasis .Thirty-nine cases metastatic carcinoma patients are in treatment group who take sorafenib orally after TACE operation ,meanwhile , the other 39 cases of control group are under TACE operation .The curative effects of these two group were then compared .To reexamine every 6-8 weeks ,then to evaluate their liver function ,therapeutic effect ,CT DSA radio-graphy and untoward effect .SPSS 13 .0 was used to calculate the meso-position survival time ,average survival time and progressive disease time statistically .Results A follow-up visit was made until May 2011 .In treatment group ,21 cases patients were survived with the rate of 54% and 18 cases were died with a rate of 46% .In control group 12 cases patients were survival with a rate of 32% and 27 cases are died with a rate of 69% .There is no case for complete remission in the two group even at the end .In treatment group ,the survival rate for 6 months ,12 months ,24 months is 92% （35/39） ,74% （29/39） ,49% （19/39） ,respectively .In control group ,the rate of them is 82% （32/39） ,64% （25/39） ,34% （14/39） ,respectively and their differences have statistical signifi-cance .The untoward effects of control group were decreased appetite ,fever ,weakness and skin reaction etc ;while the control group were nausea ,vomiting ,fever and ache etc .The untoward effects of the two groups could be remitted by symptomatic tr

关 键 词：肝肿瘤 药物疗法 联合 索拉非尼 

分 类 号：R735.7[医药卫生—肿瘤]